WO2011129549A3 - Ph 민감성 금속 나노 입자를 이용한 항암제 전달 시스템 - Google Patents

Ph 민감성 금속 나노 입자를 이용한 항암제 전달 시스템 Download PDF

Info

Publication number
WO2011129549A3
WO2011129549A3 PCT/KR2011/002461 KR2011002461W WO2011129549A3 WO 2011129549 A3 WO2011129549 A3 WO 2011129549A3 KR 2011002461 W KR2011002461 W KR 2011002461W WO 2011129549 A3 WO2011129549 A3 WO 2011129549A3
Authority
WO
WIPO (PCT)
Prior art keywords
anticancer drug
metal nanoparticles
sensitive metal
delivery system
drug delivery
Prior art date
Application number
PCT/KR2011/002461
Other languages
English (en)
French (fr)
Other versions
WO2011129549A2 (ko
WO2011129549A9 (ko
Inventor
김성지
남주택
Original Assignee
포항공과대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포항공과대학교 산학협력단 filed Critical 포항공과대학교 산학협력단
Priority to CN2011800189200A priority Critical patent/CN102858323A/zh
Priority to US13/640,605 priority patent/US9757474B2/en
Priority to JP2013504807A priority patent/JP5685308B2/ja
Priority to EP11769015.6A priority patent/EP2559429A4/en
Publication of WO2011129549A2 publication Critical patent/WO2011129549A2/ko
Publication of WO2011129549A9 publication Critical patent/WO2011129549A9/ko
Publication of WO2011129549A3 publication Critical patent/WO2011129549A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Ceramic Engineering (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 pH 민감성 금속 나노 입자에 항암제를 결합하여 암세포에서 분리함으로서, 암세포내에 효과적으로 항암제를 전달하는 방법에 관한 것이다. 본 발명에 따른 pH 민감성 금속 나노입자는 광열치료에 의해 가열될 수 있어, 분리된 항암제와 함께 암세포를 효과적으로 사멸한다.
PCT/KR2011/002461 2010-04-15 2011-04-07 Ph 민감성 금속 나노 입자를 이용한 항암제 전달 시스템 WO2011129549A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN2011800189200A CN102858323A (zh) 2010-04-15 2011-04-07 利用了pH敏感性金属纳米粒子的抗癌剂传递系统
US13/640,605 US9757474B2 (en) 2010-04-15 2011-04-07 Anticancer agent delivery system using pH-sensitive metal nanoparticles
JP2013504807A JP5685308B2 (ja) 2010-04-15 2011-04-07 ｐＨ感受性金属ナノ粒子を用いた抗癌剤伝達システム
EP11769015.6A EP2559429A4 (en) 2010-04-15 2011-04-07 ANTICANCER DRUG DELIVERY SYSTEM USING PH-SENSITIVE METAL NANOPARTICLES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100034880A KR101196667B1 (ko) 2010-04-15 2010-04-15 피에이치 민감성 금속 나노 입자를 이용한 항암제 전달 시스템
KR10-2010-0034880 2010-04-15

Publications (3)

Publication Number Publication Date
WO2011129549A2 WO2011129549A2 (ko) 2011-10-20
WO2011129549A9 WO2011129549A9 (ko) 2011-12-15
WO2011129549A3 true WO2011129549A3 (ko) 2012-02-02

Family

ID=44799133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/002461 WO2011129549A2 (ko) 2010-04-15 2011-04-07 Ph 민감성 금속 나노 입자를 이용한 항암제 전달 시스템

Country Status (6)

Country Link
US (1) US9757474B2 (ko)
EP (1) EP2559429A4 (ko)
JP (1) JP5685308B2 (ko)
KR (1) KR101196667B1 (ko)
CN (1) CN102858323A (ko)
WO (1) WO2011129549A2 (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
CN102989016A (zh) * 2012-11-05 2013-03-27 浙江大学 一种具有pH敏感性的纳米微粒材料及其制备方法
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US9649381B2 (en) 2013-11-06 2017-05-16 Wayne State University Transporter protein-coupled nanodevices for targeted drug delivery
US9874554B1 (en) 2014-07-16 2018-01-23 Verily Life Sciences Llc Aptamer-based in vivo diagnostic system
WO2016046847A1 (en) 2014-09-23 2016-03-31 Council Of Scientific & Industrial Research Metal embedded hydrophilic polymer for drug delivery applications
AU2016295602B2 (en) 2015-07-22 2019-11-14 Gnt Biotech & Medicals Corporation PH-sensitive linkers for delivering a therapeutic agent
AU2016298210B2 (en) 2015-07-28 2021-12-09 Board Of Regents, The University Of Texas System Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
US10888551B2 (en) 2016-02-24 2021-01-12 Indian Institute Of Technology, Bombay Drug delivery system
CN108057120A (zh) * 2016-11-08 2018-05-22 首都师范大学 酚铁络合物在作为光热转换材料中的应用
JP7017258B2 (ja) * 2017-01-09 2022-02-08 ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ 腫瘍治療のための標的化されたドキソルビシン－金ナノコンジュゲート
KR102300092B1 (ko) 2018-11-05 2021-09-09 가톨릭대학교 산학협력단 pH 민감성 탄소 나노입자, 이의 제조방법 및 이를 이용한 약물전달
KR102174177B1 (ko) * 2018-11-19 2020-11-05 포항공과대학교 산학협력단 수용액 이상계 나노필터 및 이를 이용한 분리방법
KR102503292B1 (ko) 2019-12-06 2023-02-24 가톨릭대학교 산학협력단 박리된 층상 이중 수산화물을 이용한 pH 민감성 복합소재 및 이를 이용한 생리활성 물질 전달체
CN111228507B (zh) * 2020-03-06 2021-01-08 郑州大学 一种hpma聚合物修饰的金纳米棒载药系统及其制备方法和应用
CN113899732B (zh) * 2021-09-30 2023-09-22 航天科工(长沙)新材料研究院有限公司 pH值敏感型配体修饰纳米金及其制备方法
KR102655577B1 (ko) 2021-11-18 2024-04-05 강원대학교산학협력단 엽산 접합 키토산으로 캡슐화된 루틴 매개 팔라듐 나노클러스터 및 그 제조방법
WO2023242766A1 (en) 2022-06-15 2023-12-21 Alembic Pharmaceuticals Limited Gold nanoconjugates

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091242A1 (en) * 2000-10-11 2002-07-11 Michel Bessodes Acid-sensitive compounds, their preparation and uses
US20050186263A1 (en) * 2002-05-19 2005-08-25 University Of Utah Research Foundation PH-sensitive polymeric micelles for drug delivery
KR100802080B1 (ko) * 2007-03-28 2008-02-11 성균관대학교산학협력단 ｐＨ 민감성 블록 공중합체 및 이를 이용한 고분자 마이셀
WO2008045804A2 (en) * 2006-10-06 2008-04-17 Polytechnic University Ph sensitive liposome composition
US20090324494A1 (en) * 2006-02-24 2009-12-31 Atgen Co., Ltd Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance
WO2010002217A2 (ko) * 2008-07-03 2010-01-07 포항공과대학교 산학협력단 페하 민감성 금속 나노 입자 및 이의 제조 방법
KR20100005589A (ko) * 2008-07-07 2010-01-15 한국과학기술원 활성산소를 감지하는 히알루론산 금 나노입자 및 이의제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074510A1 (de) * 2002-03-05 2003-09-12 Universitaet Ulm Dithiolan-derivate zur immobilisierung von biomolekülen auf edelmetallen und halbleitern
CN101438252A (zh) * 2004-10-07 2009-05-20 爱莫里大学 多功能纳米粒子共轭体及其应用
US7601331B2 (en) * 2004-11-10 2009-10-13 National University Of Singapore NIR-sensitive nanoparticle
KR20080064270A (ko) 2007-01-04 2008-07-09 홍성표 자개타일의 제작방법
WO2008147481A1 (en) * 2007-02-09 2008-12-04 Northeastern University Precision-guided nanoparticle systems for drug delivery
EP2217063B1 (en) * 2007-11-08 2014-12-17 Virginia Tech Intellectual Properties, Inc. Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents
JP2011515330A (ja) * 2008-01-30 2011-05-19 ファルマ・マール・ソシエダード・アノニマ 改良抗腫瘍治療剤
WO2009105662A1 (en) * 2008-02-21 2009-08-27 Immunolight, Llc. Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (pepst) and exciton-plasmon enhanced phototherapy (epep)
US20130023714A1 (en) * 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
EP2210616A1 (en) * 2009-01-21 2010-07-28 Centre National de la Recherche Scientifique Multifunctional stealth nanoparticles for biomedical use
US9138418B2 (en) * 2009-12-09 2015-09-22 William Marsh Rice University Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091242A1 (en) * 2000-10-11 2002-07-11 Michel Bessodes Acid-sensitive compounds, their preparation and uses
US20050186263A1 (en) * 2002-05-19 2005-08-25 University Of Utah Research Foundation PH-sensitive polymeric micelles for drug delivery
US20090324494A1 (en) * 2006-02-24 2009-12-31 Atgen Co., Ltd Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance
WO2008045804A2 (en) * 2006-10-06 2008-04-17 Polytechnic University Ph sensitive liposome composition
KR100802080B1 (ko) * 2007-03-28 2008-02-11 성균관대학교산학협력단 ｐＨ 민감성 블록 공중합체 및 이를 이용한 고분자 마이셀
WO2010002217A2 (ko) * 2008-07-03 2010-01-07 포항공과대학교 산학협력단 페하 민감성 금속 나노 입자 및 이의 제조 방법
KR20100005589A (ko) * 2008-07-07 2010-01-15 한국과학기술원 활성산소를 감지하는 히알루론산 금 나노입자 및 이의제조방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J.-Y.SHIM ET AL.: "Reversible aggregation of gold nanoparticles induced by pH dependent conformational transitions of a self-assembled polypeptide", JOURNAL OF COLLOID AND INTERFACE SCIENCE, vol. 316, 2007, pages 977 - 983, XP022328699 *
M. PRABAHARAN ET AL.: "Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery", BIOMATERIALS, vol. 30, 2009, pages 6065 - 6075, XP026524673 *
See also references of EP2559429A4 *

Also Published As

Publication number Publication date
KR20110115398A (ko) 2011-10-21
JP5685308B2 (ja) 2015-03-18
EP2559429A2 (en) 2013-02-20
US20130331764A9 (en) 2013-12-12
JP2013523877A (ja) 2013-06-17
WO2011129549A2 (ko) 2011-10-20
KR101196667B1 (ko) 2012-11-02
EP2559429A4 (en) 2016-03-23
CN102858323A (zh) 2013-01-02
WO2011129549A9 (ko) 2011-12-15
US20130138032A1 (en) 2013-05-30
US9757474B2 (en) 2017-09-12

Similar Documents

Publication Publication Date Title
WO2011129549A3 (ko) Ph 민감성 금속 나노 입자를 이용한 항암제 전달 시스템
WO2010008582A3 (en) Phagocytic cell delivery of rnai
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
MX2015000428A (es) Composiciones y metodos para regular celulas t car.
EP2722765A4 (en) CONTENT SYSTEM, CONTROL UNIT AND CONTENT PROCESSING
DK3679934T3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
EP2591792A4 (en) NUCLEIC ACID ADMINISTRATION COMPOSITION, EXCIPIENT COMPOSITION, PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACID ADMINISTRATION COMPOSITION OR EXCIPIENT COMPOSITION, AND NUCLEIC ACID DELIVERY METHOD
WO2012104655A3 (en) Compostions and methods for treating chronic inflammation and inflammatory diseases
MY179194A (en) Process for preparing therapeutic nanoparticles
EP2586494A4 (en) BOLUS, METHOD FOR MANUFACTURING BOLUS, PARTICLE BEAM THERAPY DEVICE, AND THERAPY PLANNING DEVICE
WO2010117957A3 (en) Methods and materials for delivering molecules
WO2012149440A3 (en) Therapeutic nuclease compositions and methods
EA032867B9 (ru) Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты
WO2014011465A3 (en) Aptamer-targeted antigen delivery
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
WO2012011693A3 (ko) 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체
WO2013163303A3 (en) Transferrin receptor aptamers and aptamer-targeted delivery
WO2011006002A3 (en) Metal-coated nanostructures and related methods
MX356801B (es) Incremento en la biodisponibilidad de fármacos en la terapia con naltrexona.
EP4233896A3 (en) Method for preparing an immunogenic lysate, the lysate obtained, dendritic cells loaded with such lysate and a pharmaceutical composition comprising the lysate or the dendritic cells
SG2013072061A (en) Method for producing modified conjugated diene-based polymer, and method for producing polymer composition
WO2012040331A3 (en) Multistage nanoparticles
EP2925352A4 (en) HONESTICAL INVASIN FOR IMMUNIZATION, DIAGNOSIS AND CELL RELEASE
EP2855693B8 (en) Process for the selective reduction of bile acids, their salts or derivatives, in a biphasic system
WO2014124155A3 (en) Methods for inducing cardiomyocyte proliferation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180018920.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11769015

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013504807

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13640605

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011769015

Country of ref document: EP